However, in the present study, we found that post-treatment hypoalbuminemia, but not low pre-treatment serum albumin level, was a risk factor that predicted poor outcome for mRCC patients who received sorafenib or sunitinib. The gene discussed is ALB; the disease is Hypoalbuminemia.